DS-8201a
D967VC00001
Phase 2 small_molecule active
Quick answer
DS-8201a for HER2 Expressing Tumors is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- HER2 Expressing Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active